A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection

Pediatrics

Volumn 101, Issue 2, 1998, Pages 214-220

  Kline, Mark W ^a,r   Van Dyke, Russell B ^b   Lindsey, Jane C ^c   Gwynne, Margaret ^d   Culnane, Mary ^e   McKinney Jr , Ross E ^f   Nichols, Sharon ^g   Mitchell, Wendy G ^h   Yogev, Ram ⁱ   Hutcheon, Nancy ^j   Balsley, James ^k   Bradley, Stacy A ^d   Crain, Marilyn ^l   Dunkle, Lisa ^m   Fishman, Irene ^k   Harris, Alice T ^a   Hetherington, Seth ⁿ   Luzuriaga, Katherine ^o   Nowak, Barbara ^p   Pedneault, Louise ^m   Purdue, Lynette ^k   Rogers, Audrey ^k   Sever, John ^q   more..

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^d Pediatric ACTG Operations Center   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j ST JOSEPH S REGIONAL MEDICAL CENTER   (United States)

^k NATIONAL INSTITUTES OF HEALTH   (United States)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^m BRISTOL MYERS SQUIBB   (United States)

ⁿ GLAXOSMITHKLINE   (United States)

^o UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^p FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^q CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^r BAYLOR COLLEGE OF MEDICINE   (United States)

more..

Author keywords

HIV infection; Infant or child; Stavudine; Zidovudine

Indexed keywords

STAVUDINE; ZIDOVUDINE;

ANEMIA; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ANTI-HIV AGENTS; BIAS (EPIDEMIOLOGY); CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INFANT; MALE; NEUTROPENIA; STAVUDINE; ZIDOVUDINE;

EID: 6844222850     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.101.2.214     Document Type: Article

References (24)

1. McKinney RE Jr, Pizzo PA, Scott GB, et al. Safety and tolerance of intermittent intravenous and oral zidovudine therapy in human immunodeficiency virus-infected pediatric patients. J Pediatr. 1990;116: 640-647
2. McKinney RE Jr, Maha MA, Connor EM, et al. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. N Engl J Med. 1991;324:1018-1025
3. Mueller BU, Butler KM, Stocker VL, et al. Clinical and pharmacokinetic evaluation of long-term therapy with didanosine in children with HIV infection. Pediatrics. 1994;94:724-731
4. Baba M, Pauwels R, Herdewijn P, et al. Both 2′,3′-dideoxythymidinene and its 2′,3′-unsaturated derivative(2′,3′-dideoxythymidine) are potent and selective inhibitors of human immunodeficiency virus in vitro. Biochemistry. 1987;142:128-134
5. Lin TS, Schinazi RF, Prusoff WH, et al. Potent and selective in vitro activity of 3′-deoxythymidine-2′-ene(3′-deoxy-2′,3′- didehydrothymidine) against human immunodeficiency virus. Biochem Pharmacol. 1987; 36:2713-2718
6. Kline MW, Dunkle LM, Church JA, et al. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics. 1995;96:247-252
7. Working Group on Antiretroviral Therapy: National Pediatric HIV Resource Center. Antiretroviral therapy and medical management of the human immunodeficiency virus-infected child. Pediatr Infect Dis J. 1993;12:513-522
8. Centers for Disease Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with human immunodeficiency virus. MMWR. 1991;40(No RR-2):1-13
9. McKinney RE Jr, Robertson WR, Duke Pediatric AIDS Clinical Trials Unit. Effect of human immunodeficiency virus infection on the growth of young children. J Pediatr. 1993;123:579-582
10. Dibley MJ, Goldsby JB, Staehling NW, et al. Development of normalized curves for the international growth reference: historical and technical considerations. Am J Clin Nutr. 1987;46:736-748
11. Roche AF, Himes JH. Incremental growth charts. Am J Clin Nutr. 1980; 33:2041-2052
12. Pagano M, Gauvreau K. Principles of Biostatistics. Wadsworth, CA: Duxbury Press; 1993
13. Wei LJ, Johnson WE. Combining dependent tests with incomplete repeated measurements. Biometrika. 1985;72:359-364
14. Englund JA, Baker CJ, Raskino C, et al. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. N Engl J Med. 1997;336:1704-1712
15. Balzarini J, Pauwels R, Baba M, et al. The in vitro and in vivo antiretrovirus activity, and intracellular metabolism of 3′-azido-2′,3′-dideoxythymidine and 2′,3′-dideoxycytidine are highly dependent on the cell species. Biochem Pharmacol. 1988;37:897-903
16. Ho HT, Hitchcock MJM. Cellular pharmacology of 2′,3′-dideoxy-2′,3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob Agents Chemother. 1989;33:844-849
17. Sommadossi J-P. Comparison of metabolism and in vitro antiviral activity of stavudine versus other 2′,3′-dideoxynucleoside analogues. J Infect Dis. 1995;171(suppl 2):S88-92
18. Lin P-F, Samanta H, Rose RE, et al. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis. 1994;170:1157-1164
19. Raboud JM, Montaner JSG, Thorne A, et al. Impact of missing data due to dropouts on estimates of the treatment effect in a randomized trial of antiretroviral therapy for HIV-infected individuals. J AIDS. 1996;12: 46-55
20. Brady MT, McGrath N, Brouwers P, et al. Randomized study of the tolerance and efficacy of high- versus low-dose zidovudine in human immunodeficiency virus-infected children with mild to moderate symptoms (AIDS Clinical Trials Group 128). J Infect Dis. 1996;173:1097-1106
21. Browne MJ, Mayer KH, Chafee SBD, et al. 2′,3′-Didehydro-3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis. 1993;167:21 -29
22. Italian Register for HIV Infection in Children. Features of children perinatally infected with HIV-1 surviving longer than 5 years. Lancet. 1994;343:191-195
23. Kline MW, Fletcher CV, Federici ME, et al. Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects. Pediatrics. 1996;97:886-890
24. Kline MW, Fletcher CV, Harris AT, et al. Combination therapy with stavudine (d4T), didanosine (ddl), and indinavir in HIV-infected children. Pediatr Res. 1997;41:124A